Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: One platform assessment of drug delivery potential

AAPS PharmSciTech

Volumn 15, Issue 2, 2014, Pages 388-399

  Mody, Nishi ^a   Tekade, Rakesh Kumar ^a,b   Mehra, Neelesh Kumar ^a   Chopdey, Prashant ^a   Jain, Narendra Kumar ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

carbon nanotubes; dendrimer; drug delivery; liposomes; nanoparticles; nanotechnology

Indexed keywords

CARBON NANOTUBE; DENDRIMER; DOCETAXEL; LIPOSOME; NANOPARTICLE; POLYGLACTIN; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; CANCER CELL; CELL SURVIVAL; CYTOTOXICITY ASSAY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FEMALE; HUMAN; HUMAN CELL; HYDROGENATION; IC 50; IN VITRO STUDY; INFRARED SPECTROSCOPY; MICHAEL ADDITION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; UTERINE CERVIX CANCER; ZETA POTENTIAL; CHEMISTRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TUMOR CELL LINE;

CELL LINE, TUMOR; DENDRIMERS; HUMANS; LACTIC ACID; LIPOSOMES; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NANOTUBES, CARBON; POLYGLYCOLIC ACID; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84898040575     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0073-3     Document Type: Article

References (57)

1. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310-6.
2. Pal DK, Nayak AK. Nanotechnology for targeted delivery in cancer therapeutics. Int J Pharm Sci Rev Res. 2010;1:1-7.
3. Tomalia DA, Naylor AM, Goddard WA. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed. 1990;29:138-75.
4. Solomon R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma. 2008;8:21-32.
5. Bawa R. Nanoparticle based therapeutics in humans: a survey. Nanotech Law Bus. 2008;5:135-55.
6. Fader AN, Rose PG. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer. 2009;19:1281-3.
7. Danhier F, Feron O, Véronique PV. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Rel. 2010;148:135-46.
8. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, et al. Multicenter phase II trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108:241-50.
9. Jiang S, Gnanasammandhan MK, Zhang Y. Optical imaging-guided cancer therapy with fluorescent nanoparticles. J R Soc Interface. 2010;7:3-18.
10. Park JH, Maltzahn GV, Xu MJ, Fogal V, Kotamraju VR, Ruoslathi E, et al. Cooperative nanomaterial system to sensitize, target and treat tumors. Proc Natl Acad Sci U S A. 2010;107:981-6.
11. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomed. 2009;4:1-7.
12. Tekade RK, Vijayarajkumar P, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev. 2009;109:49-87.
13. Li Y, Wang J, Wientjes MG, Au JL. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev. 2012;64:29-39.
14. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor targeted drug delivery based on EPR-effect. Euro J Pharm Biopharm. 2009;71:409-19.
15. Panyala NR, Penamendez EM, Havel J. Gold and nano-gold in medicine: overview, toxicology and perspectives. J App Biomed. 2009;7:75-91.
16. Weili Q, Bochu W, Yazhou W, Lichun Y, Yiqiong Z, Pengyu S. Cancer therapy based on nanomaterial and nanocarrier systems. J Nanomat. 2010;1:1-9.
17. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Del Rev. 2011;63:131-5.
18. Maheshwari RGS, Tekade RK, Sharma PA, Gajanan D, Tyagi A, Patel RP, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J. 2012;20:161-70.
19. Song KC, Lee HS, Choung Y, Cho KI, Ahn Y, Choi EJ. The effect of organic phase on the particle size of poly (d, l-lactide-co-glycolide) nanoparticles. Colloid Surf A: Physicochem Eng Aspects. 2006;276:162-7.
20. Tekade RK, Dutta T, Tyagi A, Bharti AC, Das BC, Jain NK. Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J Drug Target. 2008;16:758-72.
21. Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol Pharma. 2009;6:940-50.
22. Agrawal U, Mehra NK, Gupta U, Jain NK. Hyperbranched dendritic nano-carriers for topical delivery of dithranol. J Drug Target. 2013;21:497-506.
23. Mehra NK, Jain AK, Lodhi N, Dubey V, Mishra D, Raj R, et al. Challenges in the use of carbon nanotubes in biomedical applications. Crit Rev Ther Drug Carr Syst. 2008;25:169-206.
24. Shen J, Huang W, Wu L, Hu Y, Ye M. Thermo-physical properties of epoxy nanocomposites reinforced with amino-functionalized multi-walled carbon nanotubes. Composites: Part A Applied Sci Manuf. 2007;38:1331-6.
25. Jain AK, Dubey V, Mehra NK, Lodhi N, Nahar M, Mishra DM, et al. Carbohydrate-conjugated multiwalled carbon nanotubes: development and characterization. Nanomed: Nanotech Biol Med. 2009;5:432-42.
26. Lin C, Wang Y, Lai Y, Yang W, Jiao F, Zhang H, et al. Incorporation of carboxylation multiwalled carbon nanotubes into biodegradable poly (lactic-co-glycolic acid) for bone tissue engineering. ColloSurf B: Biointerfaces. 2011;83:367-75.
27. Li J, Zhang Y. Cutting of multi walled carbon nanotube. App Surf Sci. 2006;252:2944-8.
28. Pruthi J, Mehra NK, Jain NK. Macrophages targeting of amphotericin B through mannosylated multiwalled carbon nanotubes. J Drug Target. 2012;20:593-604.
29. Singh R, Mehra NK, Jain V, Jain NK. Gemcitabine-loaded smart carbon nanotubes for effective targeting to cancer cell. J Drug Target. 2013;21:581-92.
30. Lodhi N, Mehra NK, Jain NK. Development and characterization of dexamethasone mesylate anchored on multi walled carbon nanotubes. J Drug Target. 2013;21:67-76.
31. Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposome without dilution. J Anal Biochem. 1978;90:809-15.
32. Senthilkumar M, Mishra P, Jain NK. Long circulating PEGylated poly (d, l-lactide-co-glycolide) nanoparticulate delivery of DTX to solid tumors. J Drug Target. 2008;16:424-35.
33. 2 receptor antagonist. Eur J Med Chem. 2009;44:1155-66.
34. Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target. 2006;14:546-56.
35. Ganesh GNK, Gowthamarajan K, Suresh RK, Senthil V, Jawahar N, Venkatesh N, et al. Formulation and evaluation of liposomal drug delivery system for an anticancer drug and the study the effect of various stabilizers based on physicochemical and in-vitro characterization. Int J Pharm Res Develop. 2011;3:27-37.
36. Mishra V, Gupta U, Jain NK. Influence of different generations of poly (propylene imine) dendrimers on human erythrocytes. Pharmazie. 2010;65:891-5.
37. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimers towards dual-drug delivery: pH responsive simultaneous kinetics. J Microencap. 2009;26:287-96.
38. Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly (propylene imine) dendrimers: a comparison. Nanomed: Nanotechnol Biol Med. 2011;7:295-304.
39. Bhadra D, Bhadra S, Jain NK. PEGylated lysine based copolymeric dendritic micelles for solubilization and delivery of artemether. J Pharm Pharm Sci. 2005;8:467-82.
40. Gajbhiye V, Vijayaraj Kumar P, Tekade RK, Jain NK. Pharmaceutical and biomedical potential of PEGylated dendrimers. Curr Pharm Design. 2007;13:415-29.
41. Dhakad RS, Tekade RK, Jain NK. Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. Curr Drug Deliv. 2013;10:477-91.
42. Ganesh T. Improved biochemical strategies for targeted delivery of taxoids. Bioorg Med Chem. 2007;15:3597-623.
43. Karousis N, Tagmatarchis N. Current progress on the chemical modification of carbon nanotubes. Chem Rev. 2010;110:5366-97.
44. Prato M, Kostas KK, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res. 2008;41:60-8.
45. Mehra NK, Jain NK. Development, characterization and cancer targeting potential of surface engineered carbon nanotubes. J Drug Target. 2013. doi: 10.3109/1061186X.2013.813028.
46. Gupta R, Mehra NK, Jain NK. Fucosylated multiwalled carbon nanotubes for kupffer cells targeting for the treatment of cytokine-induced liver damage. Pharm Research. 2013. doi: 10.1007/s11095-013-1162-9.
47. Faranz E, Rassoul D, Hossein MG, Nasser OS, Hadi E, Fatemeh A. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly (lactide-co glycolide) nanoparticles. Anticancer Drug. 2010;21:43-52.
48. Kuzmany H, Kukovecz A, Simon F, Holzweber M, Kramberger C, Pichler T. Functionalization of carbon nanotubes. Synth Met. 2004;141:113-22.
49. Balasubramanian SV, Alderfer JL, Straubinger RM. Solvent and concentration dependent molecular interactions of taxol (paclitaxel). J Pharm Sci. 1994;83:1470-6.
50. Thakur S, Tekade RK, Jain NK. The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers. J. Nanoparticle Res. 2013.
51. Dwivedi P, Tekade RK, Jain NK. Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in alzheimer's disease. Curr Nanoscience. 2013;9:46-55.
52. Jain NK, Mishra V, Mehra NK. Targeted drug delivery to macrophages. Exp Opin Drug Deliv. 2013;10:353-67.
53. Kam NWS, Dai H. Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J Am Chem Soc. 2005;127:6021-6.
54. Jain NK, Tekade RK. Drug delivery strategies for poorly water-soluble drugs. Kent: Wiley Blackwell; 2012. p. 373-409.
55. Tekade RK, Chougule MB. Formulation development and evaluation of hybrid nanocarrier for cancer therapy: Taguchi orthogonal array based design. Biomed Res Int. 2013. doi: 10.1155/2013/712678.
56. Mehra NK, Mishra V, Jain NK. A review of ligand tethered surface engineered carbon nanotubes. Biomat. 2013. doi: 10.032/2013.
57. Youngren SR, Tekade RK, Gustilo B, Hoffmann PR, Chougule MB. STAT6 siRNA matrix-loaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells. Biomed Res Int. 2013;2013:858946. doi: 10.1155/2013/858946.